Clinical Trials

A key component of JDRF’s research strategy is the support of clinical trials because they help advance work that has been tested extensively in the lab to testing in people.  These real-life studies are when we truly put new therapies designed to prevent, treat or cure type 1 diabetes (T1D) to the test. 

How Can I Contribute to Clinical Research?

Clinical trials include people who volunteer to take part. JDRF is funding many clinical trials, and one of the biggest challenges is finding volunteers to take part in studies. 80% of T1D trials are delayed, largely because of lack of participants. By participating in a clinical trial, you are helping all people living with T1D, by enabling research towards better health outcomes and cures. 

Choosing to participate in a clinical trial is a very personal decision. Early access to promising new treatment can be an enormous benefit. Others have found that by participating in a clinical trial, they learned more about their health or T1D management. And it can be motivating to know you are contributing to helping accelerate research that can improve the lives of people living with chronic conditions. 

Find a T1D Clinical Trial  

Multiple T1D trials are taking place in Canada, many of them funded by JDRF. To learn more about these JDRF-funded trials and how to participate, click on the links below:

Actively recruiting trials               Upcoming trials

To learn about Canadian T1D trials enrolling near you, consider joining Connect1d Canada

Did you know that we only have an estimation of how many people live with T1D in Canada, and limited data on which to base improvements in policy, clinical care, and research? And that almost every T1D clinical study is delayed because of slow recruitment? Be a part of a solution, and join Connect1d Canada, a Canadian T1D registry designed to inform future policy, research, and healthcare priorities.

For more information on this JDRF-funded initiative:

Visit Connect1d Canada


Find Out About T1D Trials in Canada and Beyond

Whether you want to learn about clinical trials, consider participating, or support a clinical trial – we want help you find the information you need. Try our T1D trial finder tool.

Legacy of JDRF-Funded Trials in Canada

Canadian clinical researchers have made an immeasurable impact upon the lives of those with diabetes, ever since Dr. Banting and Best first discovered the insulin hormone and its role in diabetes. A highlight in our legacy is JDRF’s Canadian Clinical Trial Network (JDRF CCTN), which was established in 2009 to accelerate innovative solutions for the management, care, and cure of T1D. The aims of JDRF’s CCTN were:

  • To create an improved, nationwide infrastructure for diabetes clinical trials in Canada, expanding clinical trial capacity;
  • To conduct advanced clinical trials of leading-edge treatments and technologies for T1D;
  • To provide Canadians with T1D access to the latest diabetes breakthroughs via participating in clinical trials; and
  • To create new partnerships between academic researchers, non-profit organizations, industry, and government to accelerate preventions, better treatments, and a cure for T1D and its complications.

Created in partnership with the Government of Canada, funding for JDRF CCTN came from a commitment of $20 million by the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), with an additional $14 million contribution from JDRF. The $34 million investment is accelerating the testing of new technologies and treatments for Canadians and individuals around the world living with T1D and its complications. A generous $3 million investment from the WB Family Foundation later enabled JDRF CCTN to expand into western Canada, helping to fund new trials in Alberta and BC.

JDRF CCTN has supported over a dozen clinical trials, as well as multiple training awards and diabetes device projects. Clinical trials enabled by JDRF CCTN include CONCEPTT, which has led to use and coverage of continuous glucose monitors in pregnant women with T1D in many countries; ViaCyte’s first trial of encapsulated, stem cell-derived therapies; and trials testing whether a drug called ustekinumab can slow disease progression in young adults just diagnosed with T1D (in progress).